Nuclear Medicine Imaging Devices: Global Market Prospects 2012-2022
Our latest pharma report - Nuclear Medicine Imaging Devices: Global Market Prospects 2012-2022 - offers a comprehensive view of the global nuclear medicine imaging systems market. The report analyses recent trends in this market and anticipates the progression in the market over the next decade with global, regional and submarket forecasts. The report also reveals the market's strengths and weaknesses, revealing areas that will experience growth and present new business opportunities. Visiongain analyses predict the global value of the nuclear medicine imaging systems market in 2011 to be worth $1.5bn. Growth in this market will be driven by new technology and varied uses of the technology.
Despite experiencing a decline in sales volume and reduced demand in the aftermath of the global economic recession, the nuclear medicine market recovered well, and has seen strong growth in recent years. Much of this growth has been linked to the advent of hybrid units, such as positron emission tomography/computed tomography (PET/CT) scans, where both anatomical and functional images can be captured. For example, the combination of Positron Emission Tomography (PET) with other imaging modalities, such as MRI (Magnetic Resonance Imaging) has allowed for the imaging of cartilage damage, previously thought unreliable.
Nuclear Medicine Imaging Devices: Market Global Market Prospects 2012-2022 report forecasts the size and value of leading national/regional markets including the US, Europe, Japan, India and China. For each of these, visiongain identifies prevailing trends and strategies that will steer this diagnostic technology over the forecast period. Developed nuclear medicine markets such as the US and UK are highly saturated and the focus is likely to be towards upgrading stand-alone PET and SPECT system with fully integrated hybrid units, that offer a high level of anatomical and functional detail. Emerging countries such as China and India will offer more opportunity, due a lack of nuclear medicine facilities and technologies, and increased healthcare spending. It has been predicted that healthcare investment in these countries is expected to double in the next seven years.
How will the nuclear medicine imaging systems market develop this decade? Which regions offer the most significant growth opportunities between 2012 and 2022? Which of the nuclear medicine based imaging devices are growing most strongly? Who are the leading companies in the nuclear medicine imaging systems market? What are some promising technological developments in the market?
Visiongain answers these critical questions and many more through the in-depth analyses that are presented in this report.
Why you should buy Nuclear Medicine Imaging Devices: Global Market Prospects 2012-2022
In this report, you will receive the following benefits in particular:
You can order this report today
Anybody with an interest in the nuclear medicine imaging systems market should gain valuable information and insight from this new study by Visiongain, which analyses one of the most important sub-sector of the diagnostic imaging industry. You can stay ahead by ordering this report today.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Despite experiencing a decline in sales volume and reduced demand in the aftermath of the global economic recession, the nuclear medicine market recovered well, and has seen strong growth in recent years. Much of this growth has been linked to the advent of hybrid units, such as positron emission tomography/computed tomography (PET/CT) scans, where both anatomical and functional images can be captured. For example, the combination of Positron Emission Tomography (PET) with other imaging modalities, such as MRI (Magnetic Resonance Imaging) has allowed for the imaging of cartilage damage, previously thought unreliable.
Nuclear Medicine Imaging Devices: Market Global Market Prospects 2012-2022 report forecasts the size and value of leading national/regional markets including the US, Europe, Japan, India and China. For each of these, visiongain identifies prevailing trends and strategies that will steer this diagnostic technology over the forecast period. Developed nuclear medicine markets such as the US and UK are highly saturated and the focus is likely to be towards upgrading stand-alone PET and SPECT system with fully integrated hybrid units, that offer a high level of anatomical and functional detail. Emerging countries such as China and India will offer more opportunity, due a lack of nuclear medicine facilities and technologies, and increased healthcare spending. It has been predicted that healthcare investment in these countries is expected to double in the next seven years.
How will the nuclear medicine imaging systems market develop this decade? Which regions offer the most significant growth opportunities between 2012 and 2022? Which of the nuclear medicine based imaging devices are growing most strongly? Who are the leading companies in the nuclear medicine imaging systems market? What are some promising technological developments in the market?
Visiongain answers these critical questions and many more through the in-depth analyses that are presented in this report.
Why you should buy Nuclear Medicine Imaging Devices: Global Market Prospects 2012-2022
In this report, you will receive the following benefits in particular:
- You will receive our assessment of the current market for nuclear medicine imaging systems, with respect to the leading segments, companies and national markets
- You will discover sales trends for the overall nuclear medicine imaging systems market from 2011 to 2022 - seeing where commercial growth will occur
- You will discover sales trends for the Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) market from 2011 to 2022, with detailed discussions of market potential
- You will receive sales forecasts for leading national/regional markets (US, Europe, Japan, India and China), with informed discussion
- You will assess leading manufacturers and products in the nuclear medicine imaging systems market, with information on the pipeline products
- You will examine the strengths, weaknesses, opportunities and threats (SWOT analysis) facing the nuclear medicine imaging systems market from 2012 onwards
- You will be able to investigate competition and opportunities influencing the nuclear medicine technology from 2012 onwards
- You will see what will stimulate and restrain the market from 2012, with analysis of the recent market trends
- You will discover the unmet needs in the market, driving the growth from 2012 onwards.
You can order this report today
Anybody with an interest in the nuclear medicine imaging systems market should gain valuable information and insight from this new study by Visiongain, which analyses one of the most important sub-sector of the diagnostic imaging industry. You can stay ahead by ordering this report today.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. EXECUTIVE SUMMARY
1.1 Sector Highlights
1.2 Aims, Scope and Format of the Report
1.3 Chapter Outline
1.4 Research and Analysis Methods
1.5 Glossary of Terms Related to Report
2. INTRODUCTION TO NUCLEAR MEDICINE
2.1 Nuclear Medicine
2.1.1 History of Nuclear Medicine
2.2 Techniques of Nuclear Medicine
2.2.1 Diagnostic Medical Imaging
2.2.2 Interventional Nuclear Medicine
3. THE NUCLEAR MEDICINE MARKET, 2010-2022
3.1 The Global Medical and Diagnostic Imaging Market, 2010
3.1.1 Medical And Diagnostic Imaging: Market Trends 2010-2022
3.2 Nuclear Medicine Market, 2010
3.3 Nuclear Medicine Market Forecast, 2011-2022
3.3.1 Nuclear Medicine: Market Trends, 2012-2022
4. POSITRON EMISSION TOMOGRAPHY MARKET, 2010-2022
4.1 Positron Emission Tomography (PET)
4.1.1 History of PET
4.2 How It Works
4.3 Types of PET Scans
4.3.1 PET/CT
4.3.2 PET/MRI
4.4 Applications of PET
4.5 Limitations of PET
4.6 PET Market, 2010
4.7 PET Market Forecast, 2011-2022
4.7.1 PET: Market Trends, 2012-2022
4.8 PET Devices Currently In Market
4.8.1 GE Healthcare
4.8.2 Philips
4.8.3 Siemens
5. SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET, 2010-2022
5.1 Single Photon Emission Computed Tomography (SPECT)
5.1.1 History of SPECT
5.2 How it Works
5.3 Types of SPECT Scans
5.3.1 SPECT/CT
5.3.2 SPECT/MRI
5.4 Applications of SPECT
5.4.1 Cardiology
5.4.2 Neurology
5.4.3 Oncology
5.5 Limitations of SPECT
5.6 SPECT Market, 2010
5.7 SPECT Market Forecast, 2011-2022
5.7.1 SPECT: Market Trends, 2012-2022
5.7.1.1 Cost Effective
5.7.1.2 Hybrid Scanning to Drive SPECT Market
5.7.1.3 Increased Approval of New Radiopharmaceuticals
5.8 SPECT Devices Currently In Market
5.8.1 GE Healthcare
5.8.2 Philips
5.8.3 Siemens
6. LEADING COMPANIES IN THE NUCLEAR MEDICINE MARKET, 2010
6.1 Intensively Competitive Market
6.2 Nuclear Medicine Market: Breakdown by Company, 2010
6.3 GE Healthcare
6.3.1 Sales and Recent Performance Analysis, 2010
6.3.1.1 Technology Sector
6.3.2 New SPECT System Promises Lower Doses
6.4 Siemens Healthcare
6.4.1 Sales And Recent Performance Analysis, 2010
6.4.1.1 Healthcare Sector
6.4.2 New Technology To Provide HD Imaging
6.5 Philips Healthcare
6.5.1 Sales and Recent Performance Analysis, 2010
6.5.1.1 Healthcare Sector
6.5.2 FDA Clearance For Philips Hybrid Technology
6.6 Other Companies
7. LEADING NATIONAL NUCLEAR MEDICINE MARKETS, 2010
7.1 Regional Breakdown of The Global Nuclear Medicine Market, 2010
7.2 The Global Nuclear Medicine Market: Regional Forecast 2012-2022
7.3 The US Market
7.4 The European Market
7.4.1 Germany and France
7.4.2 Italy
7.4.3 Spain
7.4.4 U.K
7.5 The Japanese Market
7.6 The Indian Market
7.7 The Chinese Market
8. SWOT ANALYSIS OF THE NUCLEAR MEDICINE MARKET, 2012
8.1 Nuclear Medicine: Industry Trends
8.2 Strengths
8.2.1 Patient Demographics
8.2.2 Safer Compared to Competitive Technologies
8.3 Weaknesses
8.3.1 Regulatory Board Approvals
8.3.2 Issues With Protocols
8.3.3 Healthcare Cutbacks
8.4 Opportunities
8.4.1 Growth in SPECT/CT Imaging
8.4.2 Globalisation
8.5 Threats
8.5.1 Medical Device Excise Tax
8.5.2 The Radioisotope Shortage
9. TECHNOLOGICAL DEVELOPMENTS IN NUCLEAR MEDICINE IMAGING MARKET
9.1 Innovative Technology Drives the Market
9.2 New Radiotracers
9.2.1 For Use In Alzheimer's disease
9.2.2 For Use In Breast Cancer
9.3 3D Imaging
9.4 Mobile Applications
9.5 Silicon Photomultipliers (SiPMs)
10. CONCLUSIONS
10.1 Overview
10.2 SPECT Exams Will Remain the Largest Segment
10.3 Prominent Companies in the Market
10.4 World Market Forecasts
10.5 Future Outlook and Concluding Remarks
Appendix A
Appendix B
Visiongain report evaluation form
1.1 Sector Highlights
1.2 Aims, Scope and Format of the Report
1.3 Chapter Outline
1.4 Research and Analysis Methods
1.5 Glossary of Terms Related to Report
2. INTRODUCTION TO NUCLEAR MEDICINE
2.1 Nuclear Medicine
2.1.1 History of Nuclear Medicine
2.2 Techniques of Nuclear Medicine
2.2.1 Diagnostic Medical Imaging
2.2.2 Interventional Nuclear Medicine
3. THE NUCLEAR MEDICINE MARKET, 2010-2022
3.1 The Global Medical and Diagnostic Imaging Market, 2010
3.1.1 Medical And Diagnostic Imaging: Market Trends 2010-2022
3.2 Nuclear Medicine Market, 2010
3.3 Nuclear Medicine Market Forecast, 2011-2022
3.3.1 Nuclear Medicine: Market Trends, 2012-2022
4. POSITRON EMISSION TOMOGRAPHY MARKET, 2010-2022
4.1 Positron Emission Tomography (PET)
4.1.1 History of PET
4.2 How It Works
4.3 Types of PET Scans
4.3.1 PET/CT
4.3.2 PET/MRI
4.4 Applications of PET
4.5 Limitations of PET
4.6 PET Market, 2010
4.7 PET Market Forecast, 2011-2022
4.7.1 PET: Market Trends, 2012-2022
4.8 PET Devices Currently In Market
4.8.1 GE Healthcare
4.8.2 Philips
4.8.3 Siemens
5. SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY MARKET, 2010-2022
5.1 Single Photon Emission Computed Tomography (SPECT)
5.1.1 History of SPECT
5.2 How it Works
5.3 Types of SPECT Scans
5.3.1 SPECT/CT
5.3.2 SPECT/MRI
5.4 Applications of SPECT
5.4.1 Cardiology
5.4.2 Neurology
5.4.3 Oncology
5.5 Limitations of SPECT
5.6 SPECT Market, 2010
5.7 SPECT Market Forecast, 2011-2022
5.7.1 SPECT: Market Trends, 2012-2022
5.7.1.1 Cost Effective
5.7.1.2 Hybrid Scanning to Drive SPECT Market
5.7.1.3 Increased Approval of New Radiopharmaceuticals
5.8 SPECT Devices Currently In Market
5.8.1 GE Healthcare
5.8.2 Philips
5.8.3 Siemens
6. LEADING COMPANIES IN THE NUCLEAR MEDICINE MARKET, 2010
6.1 Intensively Competitive Market
6.2 Nuclear Medicine Market: Breakdown by Company, 2010
6.3 GE Healthcare
6.3.1 Sales and Recent Performance Analysis, 2010
6.3.1.1 Technology Sector
6.3.2 New SPECT System Promises Lower Doses
6.4 Siemens Healthcare
6.4.1 Sales And Recent Performance Analysis, 2010
6.4.1.1 Healthcare Sector
6.4.2 New Technology To Provide HD Imaging
6.5 Philips Healthcare
6.5.1 Sales and Recent Performance Analysis, 2010
6.5.1.1 Healthcare Sector
6.5.2 FDA Clearance For Philips Hybrid Technology
6.6 Other Companies
7. LEADING NATIONAL NUCLEAR MEDICINE MARKETS, 2010
7.1 Regional Breakdown of The Global Nuclear Medicine Market, 2010
7.2 The Global Nuclear Medicine Market: Regional Forecast 2012-2022
7.3 The US Market
7.4 The European Market
7.4.1 Germany and France
7.4.2 Italy
7.4.3 Spain
7.4.4 U.K
7.5 The Japanese Market
7.6 The Indian Market
7.7 The Chinese Market
8. SWOT ANALYSIS OF THE NUCLEAR MEDICINE MARKET, 2012
8.1 Nuclear Medicine: Industry Trends
8.2 Strengths
8.2.1 Patient Demographics
8.2.2 Safer Compared to Competitive Technologies
8.3 Weaknesses
8.3.1 Regulatory Board Approvals
8.3.2 Issues With Protocols
8.3.3 Healthcare Cutbacks
8.4 Opportunities
8.4.1 Growth in SPECT/CT Imaging
8.4.2 Globalisation
8.5 Threats
8.5.1 Medical Device Excise Tax
8.5.2 The Radioisotope Shortage
9. TECHNOLOGICAL DEVELOPMENTS IN NUCLEAR MEDICINE IMAGING MARKET
9.1 Innovative Technology Drives the Market
9.2 New Radiotracers
9.2.1 For Use In Alzheimer's disease
9.2.2 For Use In Breast Cancer
9.3 3D Imaging
9.4 Mobile Applications
9.5 Silicon Photomultipliers (SiPMs)
10. CONCLUSIONS
10.1 Overview
10.2 SPECT Exams Will Remain the Largest Segment
10.3 Prominent Companies in the Market
10.4 World Market Forecasts
10.5 Future Outlook and Concluding Remarks
Appendix A
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 3.1 Diagnostic & Medical Imaging Market: 2010 Product Sales ($bn) and Market Shares (%), By Modality
Table 3.2 Nuclear Medicine Market: 2010 Net Sales ($bn) and Market Shares (%), By Technique
Table 3.3 Nuclear Medicine Market Forecast ($bn) By Segment, 2010-2022
Table 4.1 PET Market: 2010 Net Sales ($bn) and Market Shares (%), By Modality
Table 4.2 Positron Emission Tomography: Market Forecast ($bn), 2010-2022
Table 5.1 SPECT: 2010 Net Sales ($bn) and Market Shares (%), By Modality
Table 5.2 Single Photon Emission Computed Tomography: Market Forecast ($bn), 2010-2022
Table 5.3 Features of Siemen's Symbia Class of SPECT/CT Scanners, 2010
Table 6.1 Leading Companies in the Nuclear Medicine Market: 2010 Healthcare Net Sales ($bn)
Table 6.2 GE Company Net Sales ($bn) and Market Shares (%) by Segment, 2010
Table 6.3 GE Technology Infrastructure: 2010 Net Sales ($m) and Market Shares (%) by Group
Table 6.4 Siemens: 2010 Net Sales ($bn) and Market Shares (%), By Sector
Table 6.5 Siemens Healthcare Sector: 2010 Net Sales ($bn) and Market Shares (%), By Product Group
Table 6.6 Philips: 2010 Net Sales ($bn) and Market Shares (%), By Business Unit
Table 6.7 Philips Healthcare Sector: 2010 Market Shares (%), By Product Group
Table 6.8 Other Companies Operating in the Nuclear Medicine Market, 2012
Table 7.1 Nuclear Medicine Market: 2010 Regional Sales ($bn) and Market Shares (%)
Table 7.2 Nuclear Medicine: Regional Market Forecast ($bn), 2010-2022
Table 7.3 Procedure Numbers (millions) of Common Applications of Diagnostic Imaging Exams Performed in The US, 2007 & 2010
Table 7.4 The Leading European Nuclear Medicine Market: National Markets by Sales ($bn), 2010
Table 7.5 Procedures Performed In Europe (%), 2005-2007
Table 7.6 The European Nuclear Medicine Market Forecast ($bn) By Region, 2010-2022
Table 8.1 SWOT Analysis of the Nuclear Medicine Market, 2012
Table 10.1 Nuclear Medicine Market Forecast ($bn), By Sector In 2010, 2016, 2018 and 2022
Table 3.1 Diagnostic & Medical Imaging Market: 2010 Product Sales ($bn) and Market Shares (%), By Modality
Table 3.2 Nuclear Medicine Market: 2010 Net Sales ($bn) and Market Shares (%), By Technique
Table 3.3 Nuclear Medicine Market Forecast ($bn) By Segment, 2010-2022
Table 4.1 PET Market: 2010 Net Sales ($bn) and Market Shares (%), By Modality
Table 4.2 Positron Emission Tomography: Market Forecast ($bn), 2010-2022
Table 5.1 SPECT: 2010 Net Sales ($bn) and Market Shares (%), By Modality
Table 5.2 Single Photon Emission Computed Tomography: Market Forecast ($bn), 2010-2022
Table 5.3 Features of Siemen's Symbia Class of SPECT/CT Scanners, 2010
Table 6.1 Leading Companies in the Nuclear Medicine Market: 2010 Healthcare Net Sales ($bn)
Table 6.2 GE Company Net Sales ($bn) and Market Shares (%) by Segment, 2010
Table 6.3 GE Technology Infrastructure: 2010 Net Sales ($m) and Market Shares (%) by Group
Table 6.4 Siemens: 2010 Net Sales ($bn) and Market Shares (%), By Sector
Table 6.5 Siemens Healthcare Sector: 2010 Net Sales ($bn) and Market Shares (%), By Product Group
Table 6.6 Philips: 2010 Net Sales ($bn) and Market Shares (%), By Business Unit
Table 6.7 Philips Healthcare Sector: 2010 Market Shares (%), By Product Group
Table 6.8 Other Companies Operating in the Nuclear Medicine Market, 2012
Table 7.1 Nuclear Medicine Market: 2010 Regional Sales ($bn) and Market Shares (%)
Table 7.2 Nuclear Medicine: Regional Market Forecast ($bn), 2010-2022
Table 7.3 Procedure Numbers (millions) of Common Applications of Diagnostic Imaging Exams Performed in The US, 2007 & 2010
Table 7.4 The Leading European Nuclear Medicine Market: National Markets by Sales ($bn), 2010
Table 7.5 Procedures Performed In Europe (%), 2005-2007
Table 7.6 The European Nuclear Medicine Market Forecast ($bn) By Region, 2010-2022
Table 8.1 SWOT Analysis of the Nuclear Medicine Market, 2012
Table 10.1 Nuclear Medicine Market Forecast ($bn), By Sector In 2010, 2016, 2018 and 2022
LIST OF FIGURES
Figure 3.1 Medical and Diagnostic Imaging Market: 2010 Product Sales ($bn), By Modality
Figure 3.2 Medical and Diagnostic Imaging Market Share (%) By Modality, 2010
Figure 3.3 Nuclear Medicine Market: 2010 Net Sales ($bn), By Technique
Figure 3.4 Nuclear Medicine Market: 2010 Market Shares (%), By Technique
Figure 3.5 Nuclear Medicine Market Forecast ($bn), 2010-2022
Figure 4.1 Positron Emission Tomography Market: 2010 Market Shares (%), By Modality
Figure 4.2 Positron Emission Tomography: Market Forecast ($bn), 2010-2022
Figure 5.1 SPECT: 2010 Market Shares (%), By Modality
Figure 5.2 Single Photon Emission Computed Tomography: Market Forecast ($bn), 2010-2022
Figure 6.1 Leading Companies in the MRI Systems Market: Healthcare Net Sales ($bn), 2010
Figure 6.2 GE Company Market Shares (%) by Sector, 2010
Figure 6.3 GE Technology Infrastructure: 2010 Net Sales ($bn), By Group
Figure 6.4 GE Technology Infrastructure: 2010 Market Shares (%), By Sector
Figure 6.5 GE Healthcare Sector: Total Sales 2006-2010 ($bn)
Figure 6.6 Siemens: 2010 Market Shares (%), By Sector
Figure 6.7 Siemens Healthcare Sector: 2010 Net Sales ($bn, By Product Group
Figure 6.8 Philips: 2010 Net Sales ($bn) and Market Shares (%), By Business Unit
Figure 6.9 Philips Healthcare Sector: 2010 Market Shares (%), By Product Group
Figure 7.1 Nuclear Medicine Market: Regional Sales ($bn), 2010
Figure 7.2 Nuclear Medicine Market: Regional Market Shares (%), 2010
Figure 7.3 The US Nuclear Medicine Market Forecast ($bn), 2010-2022
Figure 7.4 Procedure Numbers (millions) of Common Applications of Diagnostic Imaging Exams Performed in The US, 2007 & 2010
Figure 7.5 The European Nuclear Medicine Market: 2010 Sales ($bn), By Region
Figure 7.6 The European Nuclear Medicine Market: 2010 Market Shares (%), By Region
Figure 7.7 Procedures Performed In Europe (%), 2005-2007
Figure 7.8 The European Nuclear Medicine Market Forecast ($bn), 2010-2022
Figure 7.9 The German and French Nuclear Medicine Market Forecasts ($bn), 2010-2022
Figure 7.10 The Italian Nuclear Medicine Market Forecast ($bn), 2010-2022
Figure 7.11 The Spanish Nuclear Medicine Market Forecast ($bn), 2010-2022
Figure 7.12 The UK Nuclear Medicine Market Forecast ($bn), 2010-2022
Figure 7.13 The Japanese Nuclear Medicine Market Forecast ($bn), 2010-2022
Figure 7.14 The Indian Nuclear Medicine Market Forecast ($bn), 2010-2022
Figure 7.15 The Chinese Nuclear Medicine Market Forecast ($bn), 2010-2022
Figure 10.1 Projected Market Size ($bn): PET, SPECT and Accessories/Equipment Market In 2010, 2016, 2018 and 2022
Figure 10.2 Projected Total Nuclear Medicine Market Size ($bn) In 2010, 2016, 2018 and 2022
COMPANIES LISTED
Bracco Diagnostics
Center for Drug Evaluation and Research (CDER)
Coulter Pharma
Covidien
Digirad Corporation
Electron
EUSA Pharma
Food and Drug Administration (FDA)
GE Healthcare
Immunomedics
Molypharma
Neoprobe
Pharmalucence
Philips
Positron Corporation
Shanghai Apex Electronics
Siemens
Figure 3.1 Medical and Diagnostic Imaging Market: 2010 Product Sales ($bn), By Modality
Figure 3.2 Medical and Diagnostic Imaging Market Share (%) By Modality, 2010
Figure 3.3 Nuclear Medicine Market: 2010 Net Sales ($bn), By Technique
Figure 3.4 Nuclear Medicine Market: 2010 Market Shares (%), By Technique
Figure 3.5 Nuclear Medicine Market Forecast ($bn), 2010-2022
Figure 4.1 Positron Emission Tomography Market: 2010 Market Shares (%), By Modality
Figure 4.2 Positron Emission Tomography: Market Forecast ($bn), 2010-2022
Figure 5.1 SPECT: 2010 Market Shares (%), By Modality
Figure 5.2 Single Photon Emission Computed Tomography: Market Forecast ($bn), 2010-2022
Figure 6.1 Leading Companies in the MRI Systems Market: Healthcare Net Sales ($bn), 2010
Figure 6.2 GE Company Market Shares (%) by Sector, 2010
Figure 6.3 GE Technology Infrastructure: 2010 Net Sales ($bn), By Group
Figure 6.4 GE Technology Infrastructure: 2010 Market Shares (%), By Sector
Figure 6.5 GE Healthcare Sector: Total Sales 2006-2010 ($bn)
Figure 6.6 Siemens: 2010 Market Shares (%), By Sector
Figure 6.7 Siemens Healthcare Sector: 2010 Net Sales ($bn, By Product Group
Figure 6.8 Philips: 2010 Net Sales ($bn) and Market Shares (%), By Business Unit
Figure 6.9 Philips Healthcare Sector: 2010 Market Shares (%), By Product Group
Figure 7.1 Nuclear Medicine Market: Regional Sales ($bn), 2010
Figure 7.2 Nuclear Medicine Market: Regional Market Shares (%), 2010
Figure 7.3 The US Nuclear Medicine Market Forecast ($bn), 2010-2022
Figure 7.4 Procedure Numbers (millions) of Common Applications of Diagnostic Imaging Exams Performed in The US, 2007 & 2010
Figure 7.5 The European Nuclear Medicine Market: 2010 Sales ($bn), By Region
Figure 7.6 The European Nuclear Medicine Market: 2010 Market Shares (%), By Region
Figure 7.7 Procedures Performed In Europe (%), 2005-2007
Figure 7.8 The European Nuclear Medicine Market Forecast ($bn), 2010-2022
Figure 7.9 The German and French Nuclear Medicine Market Forecasts ($bn), 2010-2022
Figure 7.10 The Italian Nuclear Medicine Market Forecast ($bn), 2010-2022
Figure 7.11 The Spanish Nuclear Medicine Market Forecast ($bn), 2010-2022
Figure 7.12 The UK Nuclear Medicine Market Forecast ($bn), 2010-2022
Figure 7.13 The Japanese Nuclear Medicine Market Forecast ($bn), 2010-2022
Figure 7.14 The Indian Nuclear Medicine Market Forecast ($bn), 2010-2022
Figure 7.15 The Chinese Nuclear Medicine Market Forecast ($bn), 2010-2022
Figure 10.1 Projected Market Size ($bn): PET, SPECT and Accessories/Equipment Market In 2010, 2016, 2018 and 2022
Figure 10.2 Projected Total Nuclear Medicine Market Size ($bn) In 2010, 2016, 2018 and 2022
COMPANIES LISTED
Bracco Diagnostics
Center for Drug Evaluation and Research (CDER)
Coulter Pharma
Covidien
Digirad Corporation
Electron
EUSA Pharma
Food and Drug Administration (FDA)
GE Healthcare
Immunomedics
Molypharma
Neoprobe
Pharmalucence
Philips
Positron Corporation
Shanghai Apex Electronics
Siemens
